Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Akums Drugs and PharmaceuticalsNSE:AKUMS +3.56%41 5-Year Yield-on-Cost % is 0.13 as of Sep. 13, 2026, which is 7% below its 10-year median of 0.14. GuruFocus rates NSE:AKUMS with a GF Score™ of 41/100. The stock has 6 warning signs investors should review. Among 507 Drug Manufacturers companies, Akums Drugs and Pharmaceuticals ranks worse than 95.07% on this metric.
The historical rank and industry rank for Akums Drugs and Pharmaceuticals's 5-Year Yield-on-Cost % or its related term are showing as below:
NSE:AKUMS'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.13 Med: 0.14 Max: 0.16
Current: 0.13
During the past 6 years, Akums Drugs and Pharmaceuticals's highest Yield on Cost was 0.16. The lowest was 0.13. And the median was 0.14.
NSE:AKUMS's 5-Year Yield-on-Cost % is ranked worse than 95.07% of 507
companies
in the Drug Manufacturers industry
Industry Median: 2.41
vs NSE:AKUMS: 0.13
Akums Drugs and Pharmaceuticals (NSE:AKUMS) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Akums Drugs and Pharmaceuticals 5-Year Yield-on-Cost % Related Terms
NSE:AKUMS vs ZTS: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Akums Drugs and Pharmaceuticals's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Akums Drugs and Pharmaceuticals 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Akums Drugs and Pharmaceuticals's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Akums Drugs and Pharmaceuticals's 5-Year Yield-on-Cost % falls into.
Akums Drugs and Pharmaceuticals 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Akums Drugs and Pharmaceuticals (NSE:AKUMS) has a 5-Year Yield-on-Cost % of 0.13 as of Sep. 13, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Akums Drugs and Pharmaceuticals and its competitors. This is near median its historical median of 0.14. Over the past decade, Akums Drugs and Pharmaceuticals' 5-Year Yield-on-Cost % has ranged from 0.13 to 0.16. According to the industry distribution chart, Akums Drugs and Pharmaceuticals ranks #482 out of 507 companies in the Drug Manufacturers industry, placing it in the top 95.1%.
Is Akums Drugs and Pharmaceuticals' 5-Year Yield-on-Cost % too high?
Akums Drugs and Pharmaceuticals' current 5-Year Yield-on-Cost % of 0.13 is near median its 10-year median of 0.14. Over the past 10 years, this metric has ranged from a low of 0.13 to a high of 0.16. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.41. Akums Drugs and Pharmaceuticals' value of 0.13 is 94.6% below this industry median. Based on the distribution chart, Akums Drugs and Pharmaceuticals ranks #482 out of 507 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Akums Drugs and Pharmaceuticals has a GF Score™ of 41/100, reflecting its overall financial health beyond just this single metric.
How does Akums Drugs and Pharmaceuticals' 5-Year Yield-on-Cost % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Akums Drugs and Pharmaceuticals ranks #482 out of 507 companies for 5-Year Yield-on-Cost %. This places Akums Drugs and Pharmaceuticals in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.41. Akums Drugs and Pharmaceuticals' value of 0.13 is 94.6% below this benchmark. Historically, Akums Drugs and Pharmaceuticals' own 5-Year Yield-on-Cost % has ranged from 0.13 to 0.16 over the past decade. While the company's 10-year median is 0.14 vs. the industry median of 2.41, Akums Drugs and Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.41, based on 507 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Akums Drugs and Pharmaceuticals's current 5-Year Yield-on-Cost % of 0.13 is 94.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Akums Drugs and Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Akums Drugs and Pharmaceuticals's current 5-Year Yield-on-Cost % is 0.13, which is near median its own 10-year median of 0.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akums Drugs and Pharmaceuticals stock overvalued right now?
Akums Drugs and Pharmaceuticals (NSE:AKUMS) has a current 5-Year Yield-on-Cost % of 0.13. The current 5-Year Yield-on-Cost % is 0.13, which is near median its 10-year median of 0.14 and 94.6% below the Drug Manufacturers industry median of 2.41. Akums Drugs and Pharmaceuticals' overall GF Score™ is 41/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Akums Drugs and Pharmaceuticals (NSE:AKUMS), the current 5-Year Yield-on-Cost % is 0.13 as of Sep. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Akums Drugs and Pharmaceuticals Ltd a pharmaceutical contract development and manufacturing organization offering a comprehensive range of pharmaceutical products and services in India and overseas. Its services include formulation research and development (R&D), preparation and filing of regulatory dossiers in the Indian and Outside markets, and other testing services. It is also engaged in the manufacturing and sale of branded pharmaceutical formulations and active pharmaceutical ingredients (APIs). It operates in five segments: Contract Development and Manufacturing Operations, Active Pharmaceutical Ingredient (API), Domestic Branded formulations, International Branded Formulations, and Trade generics. Key revenue is generated from Contract Development and Manufacturing Operations.
41GF Score
Get the complete analysis for NSE:AKUMS
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:AKUMS has been successfully added to your 
